Jonathan Chang
Stock Analyst at Leerink Partners
(0.62)
# 4,048
Out of 5,030 analysts
88
Total ratings
29.73%
Success rate
-19.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Downgrades: Market Perform | $21 → $3 | $4.50 | -33.33% | 10 | Jul 22, 2025 | |
| ZLAB Zai Lab | Maintains: Outperform | $73 → $75 | $28.27 | +165.35% | 9 | Jun 30, 2025 | |
| GMAB Genmab | Upgrades: Outperform | $27 | $33.17 | -18.60% | 10 | Feb 13, 2025 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $33.56 | +120.50% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $25.60 | -57.03% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $13.78 | +270.10% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $90 → $75 | $5.93 | +1,164.76% | 12 | Jan 10, 2023 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $8.17 | +512.00% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $54.10 | -44.55% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $1.65 | +627.27% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $325 → $350 | $9.88 | +3,442.51% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $9.87 | +163.42% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.20 | +1,399.25% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $9.84 | +184.55% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $14.77 | +258.84% | 7 | Aug 5, 2021 |
Replimune Group
Jul 22, 2025
Downgrades: Market Perform
Price Target: $21 → $3
Current: $4.50
Upside: -33.33%
Zai Lab
Jun 30, 2025
Maintains: Outperform
Price Target: $73 → $75
Current: $28.27
Upside: +165.35%
Genmab
Feb 13, 2025
Upgrades: Outperform
Price Target: $27
Current: $33.17
Upside: -18.60%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $33.56
Upside: +120.50%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $25.60
Upside: -57.03%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $13.78
Upside: +270.10%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $90 → $75
Current: $5.93
Upside: +1,164.76%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $8.17
Upside: +512.00%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $54.10
Upside: -44.55%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $1.65
Upside: +627.27%
Aug 9, 2022
Maintains: Outperform
Price Target: $325 → $350
Current: $9.88
Upside: +3,442.51%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.87
Upside: +163.42%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.20
Upside: +1,399.25%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $9.84
Upside: +184.55%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $14.77
Upside: +258.84%